Answers are grounded in this paper and cite their sources.
Whether the market entry of newer advanced therapies is associated with changes in surgery rates for inflammatory bowel disease in routine clinical practice remains unclear. We aimed to describe surgery rates for Crohn’s disease and ulcerative colitis in Japan around the market-entry milestones of advanced therapies. This interrupted time-series study used a large-scale, outpatient-inclusive health insurance claims database from Japan (2012–2020). Prespecified intervention points were the market-entry months of ustekinumab for Crohn’s disease (May 2017) and vedolizumab for ulcerative colitis (November 2018). The primary outcome was monthly surgery rates, modeled using segmented Poisson regression with an offset for patients at risk. The cohorts included 5,411 patients with Crohn’s disease and 37,052 with ulcerative colitis. Surgery rates declined during the pre-intervention period (incidence rate ratios [95% confidence intervals]: Crohn’s disease, 0.993 [0.988–0.999]; ulcerative colitis, 0.994 [0.988–1.001]). No evidence of a level or post-intervention trend change was observed at the intervention points (Crohn’s disease: level change, 0.924 [0.708–1.202]; trend change, 1.000 [0.984–1.015]; ulcerative colitis: level change, 0.883 [0.588–1.309]; trend change, 1.008 [0.984–1.032]). Surgery rates showed a gradual pre-existing decline with no detectable level or trend change around these market-entry milestones. These findings suggest that changes in surgical rates may occur gradually rather than as an abrupt shift around a single market-entry milestone.
No takes yet. Share an insight, caveat, or question.
Mori et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: